CN110742892A - 一种12H-吲唑[2,1-a]噌啉-12-酮类化合物的应用 - Google Patents

一种12H-吲唑[2,1-a]噌啉-12-酮类化合物的应用 Download PDF

Info

Publication number
CN110742892A
CN110742892A CN201910972063.6A CN201910972063A CN110742892A CN 110742892 A CN110742892 A CN 110742892A CN 201910972063 A CN201910972063 A CN 201910972063A CN 110742892 A CN110742892 A CN 110742892A
Authority
CN
China
Prior art keywords
nmr
cdcl
found
indazole
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910972063.6A
Other languages
English (en)
Other versions
CN110742892B (zh
Inventor
侯卫
白芮松
阮奔放
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University of Technology ZJUT
Original Assignee
Zhejiang University of Technology ZJUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University of Technology ZJUT filed Critical Zhejiang University of Technology ZJUT
Priority to CN201910972063.6A priority Critical patent/CN110742892B/zh
Publication of CN110742892A publication Critical patent/CN110742892A/zh
Application granted granted Critical
Publication of CN110742892B publication Critical patent/CN110742892B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种12H‑吲唑[2,1‑a]噌啉‑12‑酮类化合物的应用，所述的12H‑吲唑[2,1‑a]噌啉‑12‑酮类化合物及其药学上可接受的盐或水合物在制备用于治疗恶性肿瘤药物中的应用。所述的化合物尤其对人前列腺癌PC‑3细胞和人胰腺癌PANC‑1细胞具有良好的抑制活性，并且能够剂量依耐性的抑制它们的增殖，具有重大应用前景。

Description

一种12H-吲唑[2,1-a]噌啉-12-酮类化合物的应用
技术领域
本发明涉及一类12H-吲唑[2,1-a]噌啉-12-酮类化合物或其药学上可接受的盐或水合物在制备抗肿瘤药物中的应用。
背景技术
癌症是当前严重影响人类健康、威胁人类生命的主要疾病之一。世界卫生组织(WHO)和各国政府卫生部门都把攻克癌症列为一项首要任务。
前列腺癌是常见的男性恶性肿瘤之一。美国2017年新发前列腺癌病例161360人，占男性恶性肿瘤发病率第一位(19％)；新增前列腺癌死亡人数26730人，占男性恶性肿瘤死亡率第三位(8％)。我国2015年新发前列腺癌病例60300人，且前列腺癌发病率以每年10％的速度增长。目前前列腺癌治疗以化疗和雄激素受体拮抗剂为主。阿比特龙是一种口服的CYP17抑制剂，属于孕烯醇酮类似物，可抑制依赖雄激素的前列腺癌的生长。但阿比特龙价格昂贵，并且使用一年左右可能会出现耐药，同时还会引起关节肿胀、高血压和心律失常等副作用，因此治疗依然有局限性。
胰腺癌是常见的消化道肿瘤，在全球范围内其死亡率已跃居所有肿瘤的前5位，并且发病率呈逐年上升趋势。我国的胰腺癌发病和死亡分别位居恶性肿瘤的第10位和第6位。但目前尚未开发出胰腺癌的特效治疗药物和策略，嘧啶核苷类似物吉西他滨仍是胰腺癌患者一线化疗的基础，其疗效有限，并且有较多的不良反应，因此临床对胰腺癌治疗的药物需求迫切。
因此，开发低毒高效的抗肿瘤新药尤其是针对前列腺癌和胰腺癌的新药仍然是当前亟待解决的问题。
发明内容
本发明的目的是提供一类通式I所示的12H-吲唑[2,1-a]噌啉-12-酮类化合物或其药学上可接受的盐或水合物在制备抗肿瘤药物中的应用。
为了实现上述目的，本发明采用如下技术方案：
一类12H-吲唑[2,1-a]噌啉-12-酮类化合物及其药学上可接受的盐或水合物在制备用于治疗各种恶性肿瘤药物中的应用，所述的12H-吲唑[2,1-a]噌啉-12-酮类化合物为下列之一：
Figure BDA0002232410330000021
Figure BDA0002232410330000031
本发明中的术语“药学上可接受的盐”是指与磷酸、硫酸、盐酸等无机酸，或醋酸、酒石酸、柠檬酸、苹果酸等有机酸，或天冬氨酸、谷氨酸等酸性氨基酸形成的盐，或与上述酸成酯或酰胺后再与无机碱形成的盐，如钠、钾、钙、铝盐和铵盐。
进一步，所述的恶性肿瘤优选为人前列腺癌或人胰腺癌。
再进一步，所述的12H-吲唑[2,1-a]噌啉-12-酮类化合物为化合物6、17、19或20。
本发明所述的式I所示的12H-吲唑[2,1-a]噌啉-12-酮类化合物按照如下方法进行制备：
将式A所示的2-苯基吲唑-3-酮类化合物和式B所示的重氮化合物和有机酸添加剂溶于有机溶剂中，在过渡金属催化剂的催化下，在0～150℃(优选为40～80℃)下反应1～5小时反应完全，得到的反应液经后处理得到式I所示的目标化合物；所述的有机溶剂为非质子性溶剂；过渡金属催化剂选自二价Ru催化体系或三价Rh催化体系；所述的式A所示的2-苯基吲唑-3-酮类化合物和式B所示的重氮化合物、过渡金属催化剂的物质的量之比为1:1.0～1.5:0.001～0.05；
反应式如下所示：
Figure BDA0002232410330000032
进一步，所述的二价Ru催化体系为“[Ru(p-cymene)(MeCN)3(SbF6)2]”或“[Ru(p-cymene)Cl2]2+银试剂”，其中p-cymene＝对异丙基甲苯，[Ru(p-cymene)Cl2]2与银试剂的物质的量之比为1:4。
所述的三价Rh催化体系为“[Cp*Rh(MeCN)3(SbF6)2]”或“[Cp*RhCl2]2+银试剂”，其中Cp*＝五甲基环戊二烯，[Cp*RhCl2]2与银试剂的物质的量之比为1:4。
进一步，所述的银试剂选自AgSbF6、AgBF4、AgNTf2、AgPF6、AgOTf或AgOCOCF3等含有较强吸电子作用酸根离子的银试剂。
本发明反应体系中加入有机酸添加剂可以促进反应进行，其中有机酸优选为AcOH、PivOH、PhCOOH、MesCOOH，有机酸与式A所示的化合物的物质的量之比为0.1～1.0:1。
进一步，所述的有机溶剂选自1,2-二氯乙烷、四氢呋喃、二氯甲烷、1,4-二氧六环、甲苯、氯仿等非质子性溶剂，优选为1,2-二氯乙烷和四氢呋喃，所述的有机溶剂的用量以式A所示化合物的物质的量计为0.5～1mL/mmol。
本发明所述反应液的后处理方法为：将反应液用硅胶拌样，经柱层析分离，以石油醚/乙酸乙酯＝0.5～8:1(v/v)为洗脱剂，收集含目标产物的洗脱剂，蒸除溶剂即得目标产物。
本发明所述的式A所述的底物2-苯基吲唑-3-酮类化合物参考以下文献制备：a)H.A.Ardakani,et al.Tetrahedron Lett.49(1979)4765-4768；b)A.Y.Shaw,etal.Synth.Commun.39(2009)2647-2663；c)Z.Wang,et al.ChemCatChem 9(2017)3637-3640.
本发明所述的式B所示的底物重氮类化合物参考以下文献制备：a)J.Rodriguez,et al.Synthesis 16(2011)2549-2552；b)P.Meffre,et al.Tetrahedron 58(2002)5159-5162.
与现有技术相比，本发明的有益效果在于：本发明所述的12H-吲唑[2,1-a]噌啉-12-酮类化合物及其药学上可接受的盐或水合物对人前列腺癌PC-3细胞和人胰腺癌PANC-1细胞具有良好的抑制活性，并且能够剂量依耐性的抑制它们的增殖，具有重大应用前景。
具体实施方式：
实施例旨在阐述而不是限制本发明的范围。
除非另有说明，本发明中采用的制备和测试方法以及设备等为本领域中常规的方法和设备。所用试剂均为分析纯或化学纯。
本发明所述的式A所述的底物2-苯基吲唑-3-酮类化合物参考以下文献制备：a)H.A.Ardakani,et al.Tetrahedron Lett.49(1979)4765-4768；b)A.Y.Shaw,etal.Synth.Commun.39(2009)2647-2663；c)Z.Wang,et al.ChemCatChem 9(2017)3637-3640.
本发明所述的式B所示的底物重氮类化合物参考以下文献制备：a)J.Rodriguez,et al.Synthesis 16(2011)2549-2552；b)P.Meffre,et al.Tetrahedron 58(2002)5159-5162.
实施例1.
Figure BDA0002232410330000051
称42mg(0.2mmol)2-苯基吲唑-3-酮，53mg(0.24mmol)苯甲酰乙酸乙酯重氮，12mg(0.2mmol)乙酸和5mg(0.006mmol)[Ru(p-cymene)(MeCN)3(SbF6)2]加入圆底反应瓶中，再加入2mL DCE溶解，在60℃下反应6小时。将反应液用硅胶拌样，硅胶柱层析(洗脱剂为石油醚：乙酸乙酯＝4：1)分离得到72.6mg黄色固体，收率95％。
1H NMR(600MHz,CDCl3)δ9.05(d,J＝8.4Hz,1H),8.00(d,J＝7.8Hz,1H),7.59(d,J＝7.8Hz,1H),7.55–7.49(m,3H),7.44(d,J＝7.2Hz,2H),7.35(td,J＝7.2,1.2Hz,1H),7.21(td,J＝7.2,1.2Hz,1H),7.18(t,J＝7.2Hz,1H),7.16–7.12(m,1H),5.61(d,J＝8.4Hz,1H),3.94(q,J＝7.2Hz,2H),0.84(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.4,157.3,138.9,136.3,133.9,131.6,131.2,130.5,129.9,129.1,128.4,125.9,123.8,123.5,122.4,120.0,116.6,116.1,112.9,110.4,61.0,13.5.HRMS(ESI)calcd for[M+H]+[C24H19N2O3]+383.1390,found 383.1382.
实施例2.
Figure BDA0002232410330000061
采用2-苯基-5-氟吲唑-3-酮(45.6mg,0.2mmol)和苯甲酰乙酸乙酯重氮(53mg,0.24mmol)为原料，按照实施例1的方法制备得到70.4mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率88％。
1H NMR(600MHz,CDCl3)δ9.02(dd,J＝8.4,1.2Hz,1H),7.64–7.58(m,2H),7.53(m,3H),7.42(m,2H),7.39–7.33(m,1H),7.23(td,J＝7.8,1.2Hz,1H),6.90(td,J＝9.0,3.0Hz,1H),5.56(dd,J＝9.6,4.2Hz,1H),3.94(q,J＝7.2Hz,2H),0.84(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.3,158.2(d,J＝242.9Hz),156.5,138.8,133.6,132.8,131.4,130.7,129.9,129.3,128.4,126.2,123.9,120.2,120.0(d,J＝2.3Hz),117.4(d,J＝9.0Hz),116.3,114.7(d,J＝7.8Hz),110.4,108.3(d,J＝23.9Hz),61.0,13.5.HRMS(ESI)calcd for[M+H]+[C24H18FN2O3]+401.1296,found 401.1294.
实施例3.
Figure BDA0002232410330000071
采用2-苯基-5-甲氧基吲唑-3-酮(48.0mg,0.2mmol)和苯甲酰乙酸乙酯重氮(53mg,0.24mmol)为原料，按照实施例1的方法制备得到70.1mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率85％。
1H NMR(600MHz,CDCl3)δ9.04(d,J＝7.8Hz,1H),7.60(t,J＝7.8Hz,1H),7.54(m,3H),7.42(d,J＝7.8Hz,2H),7.38–7.33(m,2H),7.22(t,J＝7.8Hz,1H),6.78(dd,J＝9.6,3.0Hz,1H),5.50(d,J＝9.6Hz,1H),3.93(q,J＝7.2Hz,2H),3.83(s,3H),0.83(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.5,157.1,155.7,139.4,133.6,131.8,131.3,130.5,129.9,129.2,128.2,125.9,123.8,122.3,120.3,117.3,116.3,114.4,109.3,102.8,60.9,55.8,13.5.HRMS(ESI)calcd for[M+H]+[C25H21N2O4]+413.1496,found 413.1501.
实施例4.
Figure BDA0002232410330000072
采用2-苯基吲唑-3-酮(42.0mg,0.2mmol)和3-甲氧基苯甲酰乙酸甲酯重氮(56.2mg,0.24mmol)为原料，按照实施例1的方法制备得到62.8mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率79％。
1H NMR(600MHz,CDCl3)δ9.05(dd,J＝8.4,1.2Hz,1H),8.06–7.95(m,1H),7.47–7.41(m,2H),7.37–7.33(m,1H),7.24–7.16(m,3H),7.12(dd,J＝8.4,2.4Hz,1H),7.01(d,J＝7.2Hz,1H),6.98–6.91(m,1H),5.76–5.68(m,1H),3.81(s,3H),3.50(s,3H).13C NMR(150MHz,CDCl3)δ166.0,160.1,157.3,138.8,136.3,133.9,132.5,131.3,130.3,128.5,125.9,123.8,123.5,122.5,122.0,119.9,116.6,116.5,116.2,114.7,113.1,110.2,55.5,51.9.HRMS(ESI)calcd for[M+H]+[C24H19N2O4]+399.1339,found 399.1341.
实施例5.
采用2-苯基吲唑-3-酮(42.0mg,0.2mmol)和4-氟苯甲酰乙酸甲酯重氮(53.3mg,0.24mmol)为原料，按照实施例1的方法制备得到71.8mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率93％。
1H NMR(600MHz,CDCl3)δ9.04(d,J＝7.8Hz,1H),8.03(m,1H),7.49–7.40(m,3H),7.38(t,J＝7.8Hz,1H),7.28(m,1H),7.25–7.18(m,4H),5.91–5.51(m,1H),3.53(s,3H).13CNMR(150MHz,CDCl3)δ165.8,163.8(d,J＝250.7Hz),157.3,138.2,136.2,133.9,132.0(d,J＝8.4Hz),131.4,128.6,127.4(d,J＝3.5Hz),125.9,123.8(d,J＝35.1Hz),122.7,119.8,116.7,116.6,116.4,116.1,112.7,110.8,51.9.HRMS(ESI)calcd for[M+H]+[C23H16FN2O3]+387.1139,found 387.1146.
实施例6.
Figure BDA0002232410330000082
采用2-苯基吲唑-3-酮(42.0mg,0.2mmol)和4-碘苯甲酰乙酸甲酯重氮(79.2mg,0.24mmol)为原料，按照实施例1的方法制备得到90.9mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率92％。
1H NMR(600MHz,CDCl3)δ9.01(d,J＝8.4Hz,1H),8.01(d,J＝7.8Hz,1H),7.89(d,J＝7.8Hz,2H),7.44(d,J＝7.8Hz,1H),7.36(t,J＝7.8Hz,1H),7.26–7.19(m,3H),7.17(d,J＝8.4Hz,2H),5.75(d,J＝7.8Hz,1H),3.51(s,3H).13C NMR(150MHz,CDCl3)δ165.7,157.3,138.4,138.2,136.3,134.0,131.5,131.4,130.9,128.7,125.9,124.0,123.8,122.7,119.8,116.7,116.1,112.8,110.7,96.9,52.0.HRMS(ESI)calcd for[M+H]+[C23H16IN2O3]+495.0200,found 495.0208.
实施例7.
Figure BDA0002232410330000091
采用2-苯基吲唑-3-酮(42.0mg,0.2mmol)和4-甲基苯甲酰乙酸甲酯重氮(52.3mg,0.24mmol)为原料，按照实施例1的方法制备得到72.6mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率95％。
1H NMR(600MHz,CDCl3)δ9.05(d,J＝7.8Hz,1H),8.05–7.92(m,1H),7.42(d,J＝7.8Hz,1H),7.38–7.28(m,5H),7.22–7.12(m,3H),5.76–5.61(m,1H),3.49(s,3H),2.49(s,3H).13C NMR(150MHz,CDCl3)δ166.1,157.3,140.8,139.2,136.3,133.9,131.2,129.8,129.6,128.4,128.3,125.8,123.8,123.5,122.4,120.0,116.5,116.1,113.1,110.3,51.8,21.6.HRMS(ESI)calcd for[M+H]+[C24H19N2O3]+383.1390,found 383.1393.
实施例8.
Figure BDA0002232410330000101
采用2-(4-氯代苯基)-吲唑-3-酮(48.8mg,0.2mmol)和苯甲酰乙酸乙酯重氮(53mg,0.24mmol)为原料，按照实施例1的方法制备得到79.2mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率95％。
1H NMR(600MHz,CDCl3)δ8.98(d,J＝9.0Hz,1H),7.97(d,J＝7.2Hz,1H),7.61(t,J＝7.2Hz,1H),7.54(m,3H),7.42(d,J＝7.2Hz,2H),7.27(dd,J＝9.0Hz,2.4Hz,1H),7.18(m,1H),7.17–7.13(m,1H),5.58(d,J＝8.4Hz,1H),3.93(q,J＝7.2Hz,2H),0.82(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.0,157.2,140.4,136.3,132.3,131.4,131.4,131.2,130.7,129.7,129.2,127.9,123.7,123.5,122.8,121.9,117.2,116.5,113.0,108.9,61.1,13.4.HRMS(ESI)calcd for[M+H]+[C24H18ClN2O3]+417.1000,found 417.0095.
实施例9.
Figure BDA0002232410330000102
称取45mg(0.2mmol)2-(4-甲基苯基)-吲唑-3-酮，53mg(0.24mmol)苯甲酰乙酸乙酯重氮，12mg(0.2mmol)乙酸和5mg(0.006mmol)[Cp*Rh(MeCN)3(SbF6)2]加入圆底反应瓶中，再加入2mL DCE溶解，在40℃下反应3小时。将反应液用硅胶拌样，硅胶柱层析(洗脱剂为石油醚:乙酸乙酯＝4:1)分离得到75.3mg黄色固体。收率95％。
1H NMR(600MHz,CDCl3)δ8.94(d,J＝8.4Hz,1H),7.99(d,J＝7.8Hz,1H),7.60(t,J＝7.8Hz,1H),7.53(t,J＝7.8Hz,2H),7.45–7.41(m,2H),7.30(s,1H),7.17(t,J＝7.8Hz,2H),7.13(t,J＝7.8Hz,1H),5.60(d,J＝8.4Hz,1H),3.94(q,J＝7.2Hz,2H),2.35(s,3H),0.83(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.6,157.0,138.6,136.1,135.7,131.7,131.5,131.0,130.5,130.0,129.1,128.9,124.2,123.5,122.4,119.8,116.6,116.1,112.9,110.4,61.0,21.2,13.5.HRMS(ESI)calcd for[M+H]+[C25H21N2O3]+397.1552,found397.1551.
实施例10.
Figure BDA0002232410330000111
采用2-(4-溴代苯基)-吲唑-3-酮(57.8mg,0.2mmol)和苯甲酰乙酸乙酯重氮(53mg,0.24mmol)为原料，按照实施例1的方法制备得到83.9mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率91％。
1H NMR(600MHz,CDCl3)δ8.94(d,J＝9.0Hz,1H),7.99(d,J＝7.2Hz,1H),7.70(d,J＝2.4Hz,1H),7.62(t,J＝7.2Hz,1H),7.54(t,J＝7.2Hz,2H),7.43(m,3H),7.20(t,J＝7.2Hz,1H),7.18–7.14(m,1H),5.59(d,J＝8.4Hz,1H),3.93(q,J＝7.2Hz,2H),0.82(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.0,157.3,140.4,136.3,132.9,131.5,131.4,130.9,130.7,129.8,129.2,126.6,123.6,122.8,122.1,119.0,117.5,116.6,113.1,108.9,61.1,13.4.HRMS(ESI)calcd for[M+H]+[C24H18BrN2O3]+461.0495,found 461.0493.
实施例11.
Figure BDA0002232410330000121
在一个圆底烧瓶中相继加入实施例10(46.1mg,0.1mmol)，Zn(CN)2(7.1mg,0.06mmol)和Pd(PPh3)4(4.6mg,0.004mmol)，随后加入1.0mL DMF，置换氮气后于100℃反应过夜，冷却至室温后，加入水和乙酸乙酯萃取，有机相拌样过硅胶柱(洗脱剂为石油醚：乙酸乙酯＝3：1)纯化得到目标化合物38.6mg(黄色固体)，收率95％。
1H NMR(600MHz,CDCl3)δ9.13(d,J＝8.4Hz,1H),8.00(dd,J＝7.2,1.8Hz,1H),7.88(d,J＝1.8Hz,1H),7.64(t,J＝7.2Hz,1H),7.59(dd,J＝9.0,1.8Hz,1H),7.56(t,J＝7.8Hz,2H),7.45–7.40(m,2H),7.25–7.16(m,2H),5.59(d,J＝8.4Hz,1H),3.94(q,J＝7.2Hz,2H),0.82(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ164.7,157.7,141.4,137.2,136.7,132.2,132.1,131.1,130.9,129.6,129.3,127.4,123.9,123.2,121.3,118.4,116.2,116.1,113.1,109.3,108.1,61.3,13.4.HRMS(ESI)calcd for[M+H]+[C25H18N3O3]+408.1343,found408.1350.
实施例12.
在一个圆底烧瓶中相继加入实施例10(46.1mg,0.1mmol)，苯硼酸(15.9mg,0.13mmol)，Na2CO3(77.4mg,0.73mmol)和Pd(PPh3)4(4.6mg,0.004mmol)，随后加入2.2mL溶剂(toluene/H2O/EtOH＝5/5/1)，置换氮气后回流反应过夜，冷却至室温后，加入水和乙酸乙酯萃取，有机相拌样过硅胶柱(洗脱剂为石油醚：乙酸乙酯＝6：1)纯化得到目标化合物41.5mg(黄色固体)，收率91％。
1H NMR(600MHz,CDCl3)δ9.13(d,J＝8.4Hz,1H),8.01(d,J＝7.2Hz,1H),7.76(d,J＝2.4Hz,1H),7.64–7.60(m,3H),7.59(dd,J＝8.4,2.4Hz,1H),7.55(t,J＝7.8Hz,2H),7.48–7.42(m,4H),7.36(t,J＝7.8Hz,1H),7.21–7.14(m,2H),5.62(d,J＝8.4Hz,1H),3.96(q,J＝7.2Hz,2H),0.85(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.5,157.2,140.1,139.2,138.7,136.3,133.1,131.6,131.3,130.6,129.9,129.2,128.8,127.5,126.9,126.9,123.6,122.6,122.4,120.4,116.5,116.5,113.0,110.2,61.1,13.5.HRMS(ESI)calcd for[M+H]+[C30H23N2O3]+459.1703,found 459.1711.
实施例13.
Figure BDA0002232410330000131
在一个圆底烧瓶中相继加入实施例10(46.1mg,0.1mmol)，吗啉(10.5mg,0.12mmol)，Cs2CO3(65.2mg,0.2mmol)，Pd(OAc)2(0.9mg,0.004mmol)和BINAP(2.5mg,0.004mmol)，随后加入2.0mL甲苯，置换氮气后反应过夜，冷却至室温后，旋干溶剂，拌样过硅胶柱(洗脱剂为石油醚：乙酸乙酯＝2：1)纯化得到目标化合物28.0mg(黄色固体)，收率60％。
1H NMR(600MHz,CDCl3)δ8.96(d,J＝9.0Hz,1H),7.98(d,J＝7.8Hz,1H),7.60(t,J＝7.8Hz,1H),7.53(t,J＝7.8Hz,2H),7.44–7.40(m,2H),7.17(t,J＝7.2Hz,1H),7.14(d,J＝3.0Hz,1H),7.12(ddd,J＝8.4,7.2,1.2Hz,1H),6.89(dd,J＝9.0,2.4Hz,1H),5.58(d,J＝8.4Hz,1H),3.91(q,J＝7.2Hz,2H),3.89–3.84(m,4H),3.26–3.12(m,4H),0.80(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.7,156.6,149.1,139.4,136.0,131.9,130.8,130.5,129.9,129.1,126.8,123.4,122.5,120.9,117.2,116.9,114.9,113.0,110.8,110.0,66.8,60.9,49.2,13.4.HRMS(ESI)calcd for[M+H]+[C28H26N3O4]+468.1918,found468.1920.
实施例14.
Figure BDA0002232410330000141
采用2-(3,5-二甲氧基苯基)-吲唑-3-酮(54.0mg,0.2mmol)和苯甲酰乙酸乙酯重氮(53mg,0.24mmol)为原料，按照实施例1的方法制备得到80.5mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝3：1)。收率91％。
1H NMR(600MHz,CDCl3)δ8.49(d,J＝2.4Hz,1H),7.94(m,1H),7.53(t,J＝7.2Hz,1H),7.47(t,J＝7.2Hz,2H),7.45–7.41(m,2H),7.15–7.08(m,2H),6.35(d,J＝2.4Hz,1H),5.72–5.63(m,1H),3.96(q,J＝7.2Hz,2H),3.92(s,3H),3.79(s,3H),1.02(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ166.7,160.9,157.5,155.0,136.8,136.4,134.7,131.3,131.1,130.4,130.3,128.7,123.4,121.9,116.2,112.8,109.9,103.2,97.1,93.8,60.9,56.1,55.8,13.9.HRMS(ESI)calcd for[M+H]+[C26H23N2O5]+443.1601,found 443.1598.
实施例15.
Figure BDA0002232410330000151
采用2-(3,4-亚甲二氧基苯基)-吲唑-3-酮(51.0mg,0.2mmol)和苯甲酰乙酸乙酯重氮(53mg,0.24mmol)为原料，按照实施例1的方法制备得到79.2mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝3：1)。收率93％。
1H NMR(600MHz,CDCl3)δ8.57(d,J＝9.0Hz,1H),7.96(d,J＝7.8Hz,1H),7.59(t,J＝7.8Hz,1H),7.52(t,J＝7.8Hz,2H),7.45(m,2H),7.16(t,J＝7.2Hz,1H),7.14–7.09(m,1H),6.79(d,J＝9.0Hz,1H),5.99(s,2H),5.61(d,J＝8.4Hz,1H),4.00(q,J＝7.2Hz,2H),1.00(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.3,157.0,145.5,141.6,137.9,136.6,131.2,130.7,130.5,130.3,129.0,128.1,123.5,122.5,116.7,112.8,110.0,107.1,105.2,101.7,61.36,13.68.HRMS(ESI)calcd for[M+H]+[C25H19N2O5]+427.1288,found427.1287.
实施例16.
Figure BDA0002232410330000152
采用2-(4-氟代苯基)-吲唑-3-酮(45.6mg,0.2mmol)和苯甲酰乙酸乙酯重氮(53mg,0.24mmol)为原料，按照实施例1的方法制备得到75.3mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率94％。
1H NMR(600MHz,CDCl3)δ9.03(dd,J＝9.0,5.4Hz,1H),7.99(d,J＝7.8Hz,1H),7.62(t,J＝7.8Hz,1H),7.54(t,J＝7.8Hz,2H),7.42(d,J＝7.2Hz,2H),7.34(dd,J＝9.6,3.0Hz,1H),7.19(t,J＝7.2Hz,1H),7.17–7.12(m,1H),7.01(ddd,J＝9.0,7.8,2.4Hz,1H),5.58(d,J＝9.0Hz,1H),3.92(q,J＝7.2Hz,2H),0.81(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.1,160.1(d,J＝243.6Hz),157.1,140.7,136.1,131.4,131.3,130.7,130.0(d,J＝2.1Hz),129.7,129.2,123.5,122.9,122.4(d,J＝9.2Hz),117.7(d,J＝8.1Hz),116.7,114.4(d,J＝22.5Hz),113.1,111.1(d,J＝26.1Hz),109.0,61.1,13.4.HRMS(ESI)calcdfor[M+H]+[C24H18FN2O3]+401.1296,found 401.1297.
实施例17.
Figure BDA0002232410330000161
采用2-(4-甲氧基苯基)-吲唑-3-酮(48.0mg,0.2mmol)和苯甲酰乙酸乙酯重氮(53mg,0.24mmol)为原料，按照实施例1的方法制备得到75.9mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率92％。
1H NMR(600MHz,CDCl3)δ9.00(d,J＝9.0Hz,1H),7.99(d,J＝7.8Hz,1H),7.60(t,J＝7.2Hz,1H),7.53(t,J＝7.2Hz,2H),7.43(d,J＝7.2Hz,2H),7.18(t,J＝7.2Hz,1H),7.16–7.08(m,2H),6.88(dd,J＝9.0,2.4Hz,1H),5.59(d,J＝9.0Hz,1H),3.93(q,J＝7.2Hz,2H),3.84(s,3H),0.83(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ165.4,157.3,156.7,139.6,136.0,131.7,130.9,130.5,129.9,129.1,127.5,123.4,122.6,121.5,117.5,116.9,113.0,112.9,109.9,109.6,61.0,55.5,13.5.HRMS(ESI)calcd for[M+H]+[C25H21N2O4]+413.1496,found 413.1499.
实施例18.
Figure BDA0002232410330000171
采用2-苯基吲唑-3-酮(42.0mg,0.2mmol)和乙酰乙酸乙酯重氮(37.4mg,0.24mmol)为原料，按照实施例1的方法制备得到55.5mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝3：1)。收率87％。
1H NMR(600MHz,CDCl3)δ8.92(d,J＝8.4Hz,1H),8.07(d,J＝8.4Hz,1H),7.63(m,2H),7.34(t,J＝7.2Hz,1H),7.32–7.28(m,1H),7.26(dd,J＝7.2,1.2Hz,1H),7.21–7.17(m,1H),4.42(q,J＝7.2Hz,2H),2.68(s,3H),1.41(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ166.7,157.0,138.1,136.9,133.3,131.9,127.8,125.8,124.1,123.6,122.9,120.3,117.3,116.2,113.7,109.6,61.5,18.4,14.3.HRMS(ESI)calcd for[M+H]+[C19H17N2O3]+321.1234,found 321.1228.
实施例19.
Figure BDA0002232410330000172
采用2-苯基吲唑-3-酮(42.0mg,0.2mmol)和乙酰乙酸甲酯重氮(34.1mg,0.24mmol)为原料，按照实施例1的方法制备得到51.5mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝3：1)。收率84％。
1H NMR(600MHz,CDCl3)δ8.91(dd,J＝8.4,0.6Hz,1H),8.07(d,J＝7.8Hz,1H),7.62(m,2H),7.36–7.32(m,1H),7.32–7.28(m,1H),7.23(dd,J＝7.8,1.2Hz,1H),7.20–7.16(m,1H),3.94(s,3H),2.66(s,3H).13C NMR(150MHz,CDCl3)δ167.2,157.0,138.6,136.9,133.3,131.9,127.8,125.8,124.1,123.7,122.9,120.2,117.4,116.2,113.7,109.3,52.3,18.4.HRMS(ESI)calcd for[M+H]+[C18H15N2O3]+307.1077,found 307.1073.
实施例20.
Figure BDA0002232410330000181
采用2-(2-甲氧基苯基)-吲唑-3-酮(48.0mg,0.2mmol)和乙酰乙酸乙酯重氮(37.4mg,0.24mmol)为原料，按照实施例1的方法制备得到56.8mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝3：1)。收率81％。
1H NMR(600MHz,CDCl3)δ8.01(d,J＝7.8Hz,1H),7.60(ddd,J＝8.4,7.2,1.2Hz,1H),7.51(d,J＝7.8Hz,1H),7.40(t,J＝7.2Hz,1H),7.24(dd,J＝16.2,8.4Hz,1H),6.94(d,J＝7.8Hz,1H),6.87(dd,J＝7.8,0.6Hz,1H),4.36(q,J＝7.2Hz,2H),3.94(s,3H),2.50(s,3H),1.36(t,J＝7.2Hz,3H).13C NMR(150MHz,CDCl3)δ166.7,157.7,151.2,144.1,141.3,131.2,128.1,126.9,124.7,123.7,120.5,119.5,116.0,115.5,112.5,110.3,61.3,56.3,17.6,14.2.HRMS(ESI)calcd for[M+H]+[C20H19N2O4]+351.1339,found 351.1346.
实施例21.
Figure BDA0002232410330000182
采用2-苯基吲唑-3-酮(44.0mg,0.2mmol)和丙酰乙酸甲酯重氮(37.4mg,0.24mmol)为原料，按照实施例9的方法制备得到58.3mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率91％。
1H NMR(500MHz,CDCl3)δ8.92(d,J＝8.5Hz,1H),8.09(d,J＝7.5Hz,1H),7.69–7.63(m,1H),7.58(d,J＝8.5Hz,1H),7.36(t,J＝7.5Hz,1H),7.33–7.28(m,1H),7.22–7.16(m,2H),3.94(s,3H),2.99(q,J＝7.5Hz,2H),1.46(t,J＝7.5Hz,3H).13C NMR(150MHz,CDCl3)δ167.1,157.1,143.2,136.3,133.3,132.3,127.8,125.9,124.2,123.6,122.9,120.4,117.3,116.3,113.1,108.7,52.3,23.4,13.3.HRMS(ESI)calcd for[M+H]+[C19H17N2O3]+321.1234,found 321.1231.
实施例22.
Figure BDA0002232410330000191
采用2-苯基吲唑-3-酮(44.0mg,0.2mmol)和3-环丙基-3-氧代丙酸甲酯重氮(40.3mg,0.24mmol)为原料，按照实施例9的方法制备得到59.8mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率90％。
1H NMR(600MHz,CDCl3)δ8.98(d,J＝7.8Hz,1H),8.06(d,J＝7.8Hz,1H),7.94(d,J＝8.4Hz,1H),7.60(t,J＝7.8Hz,1H),7.35–7.28(m,2H),7.24(d,J＝7.8Hz,1H),7.17(t,J＝7.8Hz,1H),3.95(s,3H),2.24–2.10(m,1H),1.20–1.11(m,2H),0.77(m,2H).13C NMR(150MHz,CDCl3)δ167.4,157.1,141.3,136.5,133.5,131.4,128.2,125.8,123.7,123.2,122.5,119.9,116.6,116.1,114.2,111.6,52.3,13.7,10.2.HRMS(ESI)calcd for[M+H]+[C20H17N2O3]+333.1234,found 333.1233.
实施例23.
Figure BDA0002232410330000201
采用2-苯基吲唑-3-酮(44.0mg,0.2mmol)和呋喃-2-甲酰乙酸甲酯重氮(46.6mg,0.24mmol)为原料，按照实施例1的方法制备得到66.5mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝4：1)。收率93％。
1H NMR(600MHz,CDCl3)δ8.99(dd,J＝8.4,1.2Hz,1H),8.01(d,J＝7.8Hz,1H),7.66(d,J＝1.2Hz,1H),7.48(dd,J＝7.8,1.2Hz,1H),7.36(t,J＝7.8Hz,2H),7.24(t,J＝7.2Hz,1H),7.19(td,J＝7.8,1.2Hz,1H),6.74(d,J＝3.0Hz,1H),6.63(dd,J＝3.3,1.8Hz,1H),5.73(d,J＝8.4Hz,1H),3.63(s,3H).13C NMR(150MHz,CDCl3)δ165.6,157.6,144.3,144.2,142.7,136.3,134.7,132.0,131.8,129.3,129.1,125.9,124.5,123.6,122.7,119.4,116.4,116.1,114.5,113.4,112.0,111.5,52.3.HRMS(ESI)calcd for[M+H]+[C21H15N2O4]+359.1026,found 359.1031.
实施例24.
Figure BDA0002232410330000202
在一个圆底烧瓶中相继加入实施例1(38.2mg,0.1mmol)，KOH(22.4mg,0.4mmol)和1.0mL乙二醇。随后在110℃反应3小时，冷却至室温后，加入3mL冰水，析出固体，过滤干燥之后过硅胶柱纯化(洗脱剂为石油醚：乙酸乙酯＝2：1)得到目标化合物35.1mg(黄色固体)，收率88％。
1H NMR(500MHz,DMSO-d6)δ8.93(dd,J＝8.3,0.9Hz,1H),7.90(d,J＝7.2Hz,1H),7.69–7.64(m,1H),7.59(t,J＝7.6Hz,2H),7.56–7.51(m,2H),7.48–7.39(m,2H),7.32–7.21(m,3H),5.53(d,J＝8.5Hz,1H),4.72(t,J＝5.4Hz,1H),3.87(t,J＝5.4Hz,2H),3.25(q,J＝5.4Hz,2H).13C NMR(125MHz,DMSO-d6)δ164.8,156.4,139.0,136.0,133.5,131.6,130.8,130.7,129.8,129.1,128.2,125.9,123.8,123.1,122.6,119.8,115.8,115.2,112.6,109.5,66.2,58.3.HRMS(ESI)calcd for[M+Na]+[C24H18N2NaO4]+421.1164,found 421.1161.
实施例25.
Figure BDA0002232410330000211
在一个圆底烧瓶中相继加入实施例18(32.0mg,0.1mmol)，KOH(22.4mg,0.4mmol)和1.0mL乙二醇。随后在110℃反应3小时，冷却至室温后，加入3mL冰水，析出固体，过滤干燥之后过硅胶柱(洗脱剂为石油醚：乙酸乙酯＝1：1)纯化得到目标化合物30.6mg(黄色固体)，收率91％。
1H NMR(500MHz,DMSO-d6)δ8.78(d,J＝8.2Hz,1H),7.97(d,J＝9.0Hz,2H),7.78–7.73(m,1H),7.43(t,J＝7.5Hz,1H),7.38–7.32(m,2H),7.27–7.22(m,1H),4.97(t,J＝5.3Hz,1H),4.42–4.28(m,2H),3.70(q,J＝5.1Hz,2H),2.68(s,3H).13C NMR(125MHz,DMSO-d6)δ166.1,156.38,139.3,136.9,132.8,132.4,127.4,125.9,123.7,123.1,123.1,120.2,116.3,115.2,115.0,108.4,66.9,58.8,17.9.HRMS(ESI)calcd for[M+Na]+[C19H16N2NaO4]+359.1008,found 359.1003.
实施例26.
采用2-(4-氟代苯基)-吲唑-3-酮(45.6mg,0.2mmol)和1,3-环己二酮重氮(33.1mg,0.24mmol)为原料，按照实施例9的制备方法得到61.5mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝0.5：1)。收率96％。
1H NMR(600MHz,CDCl3)δ8.84(dd,J＝9.0,5.4Hz,1H),8.53(dd,J＝11.4,3.0Hz,1H),8.09(d,J＝7.8Hz,1H),7.74–7.65(m,2H),7.44(dd,J＝10.5,3.9Hz,1H),6.97(ddd,J＝9.0,7.8,3.0Hz,1H),3.3(t,J＝6.2Hz,2H),2.70–2.55(m,2H),2.33–2.20(m,2H).13C NMR(100MHz,CDCl3)δ194.1,160.06(d,J＝243.7Hz),156.5,151.6,136.3,132.3,129.2,124.4,121.7(d,J＝10.0Hz),118.7,117.1(d,J＝8.3Hz),114.4,113.9(d,J＝23.2Hz),113.3(d,J＝27.6Hz),108.5,37.7,28.2,20.9.HRMS(ESI)calcd for[M+H]+[C19H14FN2O2]+321.1039,found 321.1037.
实施例27.
Figure BDA0002232410330000222
采用2-(4-碘代苯基)-吲唑-3-酮(67.2mg,0.2mmol)和1,3-环戊二酮重氮(29.8mg,0.24mmol)为原料，按照实施例9的方法制备得到76.2mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝0.5：1)。收率92％。
1H NMR(500MHz,DMSO-d6)δ8.65(d,J＝8.5Hz,1H),8.57(d,J＝2.0Hz,1H),8.03(d,J＝8.0Hz,1H),7.97(d,J＝8.5Hz,1H),7.87(t,J＝8.0Hz,1H),7.71(dd,J＝8.5,2.0Hz,1H),7.53(t,J＝7.5Hz,1H),3.46–3.41(m,2H),2.69–2.63(m,2H).13C NMR(125MHz,DMSO-d6)δ198.2,161.8,156.3,136.0,135.2,133.3,131.7,129.5,124.5,123.4,120.2,117.1,116.2,113.1,108.1,90.5,34.0,25.0.HRMS(ESI)calcd for[M+H]+[C18H12IN2O2]+414.9943,found 414.9936.
实施例28.
Figure BDA0002232410330000231
采用2-(2-氟代苯基)-吲唑-3-酮(45.6mg,0.2mmol)和1,3-环戊二酮重氮(29.8mg,0.24mmol)为原料，按照实施例9的方法制备得到52.1mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝0.5：1)。收率85％。
1H NMR(500MHz,CD2Cl2)δ8.10(d,J＝7.0Hz,1H),8.04(d,J＝8.0Hz,1H),7.81–7.75(m,1H),7.60(d,J＝8.5Hz,1H),7.53(t,J＝7.5Hz,1H),7.30(td,J＝8.0,5.0Hz,1H),7.16–7.09(m,1H),3.23–3.15(m,2H),2.72–2.65(m,2H).13C NMR(125MHz,CD2Cl2)δ198.6,165.5,157.8,152.9(d,J＝256.8Hz),139.6,133.4,129.1(d,J＝8.1Hz),126.2(d,J＝13.1Hz),126.0,124.6,124.2,118.7(d,J＝30.0Hz),117.9(d,J＝12.6Hz),117.2(d,J＝20.5Hz),113.5,34.6,25.6.HRMS(ESI)calcd for[M+H]+[C18H12FN2O2]+307.0883,found307.0879.
实施例29.
Figure BDA0002232410330000241
采用2-(3,5-二甲氧基苯基)-吲唑-3-酮(54.0mg,0.2mmol)和1,3-环戊二酮重氮(29.8mg,0.24mmol)为原料，按照实施例9的方法制备得到62.7mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝0.5：1)。收率90％。
1H NMR(500MHz,DMSO-d6)δ8.14(d,J＝2.5Hz,1H),7.97(d,J＝8.0Hz,1H),7.93(d,J＝8.5Hz,1H),7.83(t,J＝8.0Hz,1H),7.48(t,J＝7.5Hz,1H),6.58(d,J＝2.0Hz,1H),3.83(s,3H),3.82(s,3H),3.36–3.28(m,2H),2.58–2.54(m,2H).13C NMR(125MHz,DMSO-d6)δ194.4,160.0,156.4,136.3,134.7,133.1,124.0,123.4,116.8,113.4,112.4,100.9,97.0,94.5,56.1,55.5,34.1,24.3.HRMS(ESI)calcd for[M+H]+[C20H17N2O4]+349.1188,found349.1184.
实施例30.
采用2-苯基吲唑-3-酮(42.0mg,0.2mmol)和丙酮基膦酸二甲酯重氮(46.1mg,0.24mmol)为原料，按照实施例1的方法制备得到69.3mg黄色固体(洗脱剂为石油醚：乙酸乙酯＝0.5：1)。收率97％。
1H NMR(600MHz,CDCl3)δ8.76(d,J＝8.4Hz,1H),8.07(d,J＝7.8Hz,1H),7.73(dd,J＝7.8,1.2Hz,1H),7.71(d,J＝8.4Hz,1H),7.65(td,J＝7.8,1.2Hz,1H),7.38(t,J＝7.8Hz,1H),7.29(td,J＝7.8,1.2Hz,1H),7.20(td,J＝7.8,1.2Hz,1H),3.77(s,3H),3.76(s,3H),3.11(d,J＝2.4Hz,3H).13C NMR(150MHz,CDCl3)δ157.2,149.9(d,J＝24.7Hz),137.5,133.4(d,J＝11.1Hz),132.1,127.4,125.9,125.4,124.1,123.7,121.3(d,J＝8.8Hz),118.5,115.8,115.1,99.2(d,J＝200.5Hz),52.3(d,J＝16.8Hz),18.6.HRMS(ESI)calcd for[M+H]+[C18H18N2O4P]+357.0999,found 357.1002.
体外抗肿瘤活性实验
采用CCK-8法并选取人前列腺癌PC-3细胞(源于日本癌症研究基金会)进行体外抗肿瘤活性评价(采用雷公藤甲素作为阳性对照)，操作如下：
1、在96孔板中接种100μL PC-3细胞悬液，每孔细胞密度为1×104个，设不含细胞的空白对照，将96孔板在培养箱预培养24小时(37℃,5％CO2)使细胞贴壁；
2、向培养孔中加入10μL不同浓度的待测化合物，每个浓度设3个平行孔(设不含药物的对照组)。在培养箱中孵育72小时后，向每孔加入10μL CCK-8溶液，将96孔板在培养箱内孵育1-4小时；
3、用酶标仪测定在450nM处的吸光度：
细胞活力(％)＝(A加药-A空白)/(A0加药-A空白)×100％
A加药：含有细胞悬液、CCK-8溶液和待测化合物溶液的孔的吸光度
A空白：不含细胞悬液，含有培养基溶液、CCK-8溶液和待测化合物溶液的孔的吸光度
A0加药：不含待测化合物溶液，含有细胞悬液、CCK-8溶液和培养基溶液的孔的吸光度
细胞抑制率(％)＝(A0加药-A加药)/(A0加药-A空白)×100％
表1、化合物在三种浓度下对PC-3细胞的抑制率
Figure BDA0002232410330000261
表1的结果表明：所测的30个化合物中有26个化合物在50μM时对PC-3细胞的抑制率大于50％，有12个化合物在5μM时对PC-3细胞的抑制率大于50％，有3个化合物在0.5μM时对PC-3细胞的抑制率大于50％。可见，这一类12H-吲唑[2,1-a]噌啉-12-酮类化合物具有良好的抗肿瘤活性，代表所述的化合物具有显著的抗肿瘤活性。
进一步选取活性较好的化合物6、8、13、15、17、19和20测试它们对人前列腺癌PC-3细胞和人胰腺癌PANC-1细胞(源于日本癌症研究基金会)的半数抑制浓度IC50。结果如表2所示：化合物6、13、15、17、19和20对PC-3细胞的IC50均小于10μM，其中6、17、19和20对PC-3细胞的IC50均小于5μM，并且化合物20对PC-3细胞的IC50为216nM。化合物6、17、19和20对PANC-1细胞的IC50均小于10μM，其中17、19和20对PANC-1细胞的IC50均小于5μM，并且化合物19和20对PANC-1细胞的IC50均小于1μM，分别为551nM和216nM。这些良好的结果进一步说明这类化合物具有显著的抗肿瘤活性。
表2、部分化合物对PC-3和PANC-1细胞的抑制活性
Figure BDA0002232410330000271
a每个实验采用9个浓度且至少重复三遍
上述实例只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人员能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所做的等效变换或修饰，都应涵盖在本发明的保护范围之内。

Claims (3)

1.一类12H-吲唑[2,1-a]噌啉-12-酮类化合物及其药学上可接受的盐或水合物在制备用于治疗各种恶性肿瘤药物中的应用，所述的12H-吲唑[2,1-a]噌啉-12-酮类化合物为下列之一：
Figure FDA0002232410320000011
2.如权利要求1所述的应用，其特征在于：所述的恶性肿瘤为人前列腺癌或人胰腺癌。
3.如权利要求2所述的应用，其特征在于：所述的12H-吲唑[2,1-a]噌啉-12-酮类化合物为化合物6、17、19或20。
CN201910972063.6A 2019-10-14 2019-10-14 一种12H-吲唑[2,1-a]噌啉-12-酮类化合物的应用 Active CN110742892B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910972063.6A CN110742892B (zh) 2019-10-14 2019-10-14 一种12H-吲唑[2,1-a]噌啉-12-酮类化合物的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910972063.6A CN110742892B (zh) 2019-10-14 2019-10-14 一种12H-吲唑[2,1-a]噌啉-12-酮类化合物的应用

Publications (2)

Publication Number Publication Date
CN110742892A true CN110742892A (zh) 2020-02-04
CN110742892B CN110742892B (zh) 2022-05-24

Family

ID=69278184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910972063.6A Active CN110742892B (zh) 2019-10-14 2019-10-14 一种12H-吲唑[2,1-a]噌啉-12-酮类化合物的应用

Country Status (1)

Country Link
CN (1) CN110742892B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111170943A (zh) * 2020-01-22 2020-05-19 浙江大学 苯并[f]环戊烷并[c]喹啉衍生物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109879827A (zh) * 2019-03-30 2019-06-14 陕西理工大学 一种新型吲唑类衍生物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109879827A (zh) * 2019-03-30 2019-06-14 陕西理工大学 一种新型吲唑类衍生物及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIN SU ET AL: "Ruthenium(II)-catalyzed synthesis of indazolonefused cinnolines via C–H coupling with diazo compounds", 《ORGANIC & BIOMOLECULAR CHEMISTRY》 *
WEI HOU ET AL: "Synthesis of Indazolo[2,1-a]Cinnolines via Rhodium (III)-Catalyzed C-H activation/annulation under mild conditions", 《TETRAHEDRON》 *
ZHANG, XIANG: "Meeting organometallic chemistry with drug discovery: C-H activation enabled discovery of a new ring system of 12H-Indazolo[2,1-a]cinnolin-12-ones with anti-proliferation activity", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111170943A (zh) * 2020-01-22 2020-05-19 浙江大学 苯并[f]环戊烷并[c]喹啉衍生物及其应用

Also Published As

Publication number Publication date
CN110742892B (zh) 2022-05-24

Similar Documents

Publication Publication Date Title
CN105622525B (zh) 用于制备抗病毒化合物的方法
CN109438522A (zh) 5-氟尿嘧啶-铂（iv）配合物、中间体、其制备方法及应用
CN110742892B (zh) 一种12H-吲唑[2,1-a]噌啉-12-酮类化合物的应用
CN108947949B (zh) 抗焦虑氘代化合物及其医药用途
CN113105468B (zh) 一种含苯并吡喃酮的多环螺吲哚酮类化合物及其制备方法和应用
CN112479974B (zh) 一种3-羰基-2,3’-联吲哚氮氧化物衍生物的制备和应用
CN111423438B (zh) 具有抗肿瘤活性的Eudistomins Y类衍生物及其制备方法和应用
CN113636970B (zh) 一种异吲哚酮的化合物、制备方法及其应用
CN113024557B (zh) 一种Peganumine A生物碱结构简化物及其应用
CN110655521B (zh) 一种12H-吲唑[2,1-a]噌啉-12-酮类化合物及其应用
CN115322136A (zh) 帕罗韦德和波普瑞韦中间体的制备方法
CN109942665A (zh) 雷公藤内酯醇衍生物及其制备方法和应用
CN108484623B (zh) 喜树碱衍生物及其制备方法与应用
CN110092789B (zh) 一种吲哚并[2,3-b]咔唑衍生物及其应用
CN112876456A (zh) 噌啉化合物pi3k激酶抑制剂及其制备方法与在制药中的应用
CN113493469A (zh) 可作为免疫调节剂的化合物、其制备方法和应用
WO2008026300A1 (fr) Agent thérapeutique dérivé de graines de neem pour les tumeurs malignes
CN110604732A (zh) 一种莪术醇衍生物在制备治疗结直肠癌药物中的应用
CN114605407B (zh) 一种吲哚喹啉酮类化合物及其合成方法和应用
CN116239594B (zh) 6-(咪唑并[1,2-a]吡啶-6-基)喹唑啉衍生物及用途
CN113929639B (zh) 一类以gstp1为靶点的抗肿瘤化合物及其制备方法与应用
CN114181222B (zh) 一种具有抗肿瘤效果氮杂环化合物的合成方法及应用
CN112142796B (zh) 可见光促进铜催化制备c-4位磷酸酯取代2-氨基异喹啉酮类衍生物的合成方法及应用
CN106478687A (zh) 以1‑(2‑吡啶)‑9‑乙基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用
CN110950878B (zh) 菲啶酮衍生物及其合成方法和抗肿瘤应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant